Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal ...

Indian equity markets opened on a cautious note, a day after recording a sharp recovery that snapped a six-week losing streak ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...

The 20-valent pneumococcal conjugate vaccine (PCV20, or Prevnar 20) produced a non-inferior immune response in adults to the 13-valent vaccine (PCV13, or Prevnar 13), with an adequate safety ...

PCV20 offers the broadest serotype coverage of any PCV, adding serotypes 8, 10A, 11A, 12F, and 15B to the PCV15 vaccine.

PCV20 includes all 13 serotypes in PCV13, along with seven additional serotypes “that are responsible for a substantial amount of the residual disease burden,” he added.

At the 2.2mcg dose, VAX-24 met the standard OPA response non-inferiority criteria (1) for all 20 serotypes common with PCV20, of which 16 serotypes (3, 4, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B ...

At the 2.2mcg dose, VAX-24 met the standard OPA response non-inferiority criteria (1) for all 20 serotypes common with PCV20, of which 16 serotypes (3, 4, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B ...